CD8+ lymphocyte subpopulations in pleural fluid are associated with longer survival in patients with malignant pleural effusion (MPE) submitted to thoracoscopic talc pleurodesis
A. Hernández Martnez, L. Gómez Izquierdo, R. Santiago Villalobos, J. Martn Juan, J. Castillo Gómez, F. Rodrguez Panadero (Seville, Spain)
Source: Annual Congress 2002 - Pleural disease
Session: Pleural disease
Session type: Thematic Poster Session
Number: 539
Disease area: Thoracic oncology
Abstract OBJECTIVE: We aimed to analyse the cellularity in pleural fluid of patients with MPE and submitted to talc pleurodesis, and correlate it with their prognosis. PATIENTS AND METHODS: Seventeen patients with MPE submitted to talc pleurodesis, and no receiving other curative treatment, were included in the study. We investigated the lymphocyte subpopulations in the pleural fluid obtained just before thoracoscopy. All patients were followed until death, or at least for one year following the procedure. RESULTS: Patients showing a higher proportion of CD8+ lymphocytes in pleural fluid had an overal increased survival, as compared with those having less than 20% CD8 (see Table below). CONCLUSION: Patients with a higher rate of CD8+ lymphocytes have a marked better prognosis, and we hypothesize that CD8+ lymphocytes in pleural fluid could play a significant role in the local control of the disease in patients with MPE, and its stimulation might have a therapeutic interest to improve their still poor prognosis. (This study was funded by grant SAS 21/99)
CD8+ lymphocytes >= 20% < 20% TOTAL SURVIVAL >= 7 months 8 (*) 3 (***) 11 SURVIVAL< 7 months 2 (**) 4 (****) 6 (*): 3 mesotheliomas, 3 carcinomas of the breast, 1 colon, 1 lung(**): 2 lung carcinomas (***): 1 mesothelioma,1 bronchoalveolar carcinoma,1 colon(****): 2 lung,1 breast,1 stomach carcinoma
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Hernández Martnez, L. Gómez Izquierdo, R. Santiago Villalobos, J. Martn Juan, J. Castillo Gómez, F. Rodrguez Panadero (Seville, Spain). CD8+ lymphocyte subpopulations in pleural fluid are associated with longer survival in patients with malignant pleural effusion (MPE) submitted to thoracoscopic talc pleurodesis. Eur Respir J 2002; 20: Suppl. 38, 539
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
The profile of neutrophils and D-dimer in pleural fluid is useful to monitor the pleurodesis process after talc poudrage in malignant pleural effusions (MPE) Source: Eur Respir J 2002; 20: Suppl. 38, 70s Year: 2002
Thoracoscopic talc poudrage induces T-lymphopenia Source: Annual Congress 2005 - What's new in the pleura Year: 2005
Histology, performance status and lymphopenia are factors of survival in patients undergoing thoracoscopy for malignant pleural effusion Source: Annual Congress 2009 - Trends in bronchoscopy Year: 2009
Predictors of successful pleurodesis for patients with malignant pleural effusions Source: Eur Respir J 2004; 24: Suppl. 48, 493s Year: 2004
Interleukin-16 in tuberculous and malignant pleural effusions Source: Eur Respir J 2005; 25: 605-611 Year: 2005
Treatment successes with talc pleurodesis at patients (pts.) with recurrent malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Comparison in effectiveness and proinflammatory mediators between talc, doxycycline and tetracycline for pleurodesis in malignant pleural effusions (MPE) Source: Annual Congress 2006 - New developments in diagnostic and therapeutic bronchoscopy and thoracoscopy Year: 2006
Day case rapid pleurodesis in malignant pleural effusion Source: Virtual Congress 2021 – Novelties in interventional pulmonology Year: 2021
Thoracoscopic talc pleurodesis‘(TTP) safety and clinical efficacy in malignant pleural effusions (MPE) Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010
Talc pleurodesis in malignant pleural effusions: A 5-year experience Source: Annual Congress 2012 - Medical access to the pleura Year: 2012
Efficacy of talc pleurodesis in patients with malignant pleural effusions Source: Annual Congress 2011 - Molecular markers: diagnosis and management of malignant pleural effusions Year: 2011
The role of thoracoscopy in the diagnosis of malignant pleural effusions (PE) Source: Eur Respir J 2002; 20: Suppl. 38, 438s Year: 2002
Thoracoscopic evaluation of the effect of tumour burden on the outcome of pleurodesis in malignant pleural effusion Source: Virtual Congress 2021 – Pleural disease and bronchoscopic lung volume reduction Year: 2021
Prognostic factors associated to survival in patients with malignant pleural effusion (MPE) undergoing talc poudrage pleurodesis (TPP) Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016
Thoracoscopic talc poudrage (TTP) in malignant (M) pleural effusion (PE): when to perform it? Source: International Congress 2019 – Interventional pulmonology: current pleural practice Year: 2019
Malignant pleural effusions Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=177 Year: 2002
The value of thoracoscopy in malignant pleural effusions Source: Eur Respir J 2001; 18: Suppl. 33, 516s Year: 2001
Effecs of systemic inflammation markers for determining success of talc pleurodeisis on patients with malignant pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 61s Year: 2003
Polarized cytokine profiles in the peripheral blood and pleural fluid from the patients with tuberculous pleurisy, pulmonary tuberculosis combined disease, and malignant pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 467s Year: 2004
Analysis of T-cell subsets in patients with tuberculous pleural effusions Source: Annual Congress 2005 - Genetics and immunobiology of tuberculosis Year: 2005